Los puntos clave no están disponibles para este artículo en este momento.
A post-hoc analysis to understand factors leading to initiation of a new rozanolixizumab cycle in the Phase 3 MycarinG and open-label extension (OLE) studies.
Mahuwala et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: